Please use this identifier to cite or link to this item:
Title: Functionalized immunostimulating complexes with protein A via lipid vinyl sulfones to deliver cancer drugs to trastuzumab-resistant HER2-overexpressing breast cancer cells.
Authors: Rodríguez-Serrano, Fernando
Mut-Salud, Nuria
Cruz-Bustos, Teresa
Gomez-Samblas, Mercedes
Carrasco, Esther
Garrido, Jose Manuel
López-Jaramillo, F Javier
Santoyo-Gonzalez, Francisco
Osuna, Antonio
Keywords: HER2;doxorubicin;nanoparticle;paclitaxel;protein A;targeted drug delivery;trastuzumab
metadata.dc.subject.mesh: Antineoplastic Agents
Breast Neoplasms
Cell Death
Cell Line, Tumor
Cell Survival
Drug Delivery Systems
Drug Resistance, Neoplasm
Flow Cytometry
MCF-7 Cells
Proto-Oncogene Mas
Receptor, ErbB-2
Staphylococcal Protein A
Issue Date: 19-Sep-2016
Abstract: Around 20%-30% of breast cancers overexpress the proto-oncogene human epidermal growth receptor 2 (HER2), and they are characterized by being very invasive. Therefore, many current studies are focused on testing new therapies against tumors that overexpress this receptor. In particular, there exists major interest in new strategies to fight breast cancer resistant to trastuzumab (Tmab), a humanized antibody that binds specifically to HER2 interfering with its mitogenic signaling. Our team has previously developed immunostimulating complexes (ISCOMs) as nanocapsules functionalized with lipid vinyl sulfones, which can incorporate protein A and bind to G immunoglobulins that makes them very flexible nanocarriers. The aim of this in vitro study was to synthesize and evaluate a drug delivery system based on protein A-functionalized ISCOMs to target HER2-overexpressing cells. We describe the preparation of ISCOMs, the loading with the drugs doxorubicin and paclitaxel, the binding of ISCOMs to alkyl vinyl sulfone-protein A, the coupling of Tmab, and the evaluation in both HER2-overexpressing breast cancer cells (HCC1954) and non-overexpressing cells (MCF-7) by flow cytometry and fluorescence microscopy. Results show that the uptake is dependent on the level of overexpression of HER2, and the analysis of the cell viability reveals that targeted drugs are selective toward HCC1954, whereas MCF-7 cells remain unaffected. Protein A-functionalized ISCOMs are versatile carriers that can be coupled to antibodies that act as targeting agents to deliver drugs. When coupling to Tmab and loading with paclitaxel or doxorubicin, they become efficient vehicles for the selective delivery of the drug to Tmab-resistant HER2-overexpressing breast cancer cells. These nanoparticles may pave the way for the development of novel therapies for poor prognosis resistant patients.
metadata.dc.identifier.doi: 10.2147/IJN.S112560
Appears in Collections:Producción 2020

Files in This Item:
File SizeFormat 
PMC5034911.pdf2,06 MBAdobe PDFView/Open

This item is protected by original copyright

This item is licensed under a Creative Commons License Creative Commons